AB-101 + nucleos(t)ide analogue

AB-101 + nucleos(t)ide analogue is a **combination therapy** under clinical investigation for the treatment of relapsed or refractory B-cell malignancies and other immune-related disorders. AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved **natural killer (NK) cell therapy** optimized for enhanced antibody-dependent cellular cytotoxicity (ADCC) in combination with monoclonal antibodies[1][3][7]. Nucleos(t)ide analogues, a class of small-molecule antiviral agents (such as entecavir, tenofovir, lamivudine, or others), inhibit viral DNA polymerase as competitive substrates and are a backbone of chronic hepatitis B therapy[4][8]. The combination leverages the cytotoxic and immune-modulating properties of NK cell therapy (AB-101) plus the viral replication suppression of nucleos(t)ide analogue(s). AB-101 is being advanced primarily by Artiva Biotherapeutics in the context of B-cell non-Hodgkin lymphoma and is considered for other immunological conditions[1][3][7].